Add knowledge
Search
de / fr / en / it
www.kmsk.ch
Strong together, Rare diseases

We support affected
Families on their way
We support affected Families on their way

The diagnosis of a rare disease pulls the rug out from under affected families, who find themselves in an unknown world after an initial shock.

This is characterized by the worries about their child, administrative and organizational challenges. What help and support services are available? What are they And who will guide them through this unknown jungle? How have other affected families master this enormous task?

The digital KMSK Knowledge Platform Rare Diseases is based on the Initiative of Manuela Stier, founder and managing director of the Förderverein für Kinder mit seltenen Diseases, in in close collaboration with our 710 affected KMSK families (Switzerland-wide), the ZHAW Winterthur, the HES-SO Wallis, competent experts and sustainable thinking sponsors.


May the may the cumulative power of knowledge and experience help the parents of the 350,000 children and Children and adolescents with a rare disease in Switzerland a little easier in their often everyday life a little easier.

Support association for children with rare diseases

Since 2014, we have been putting our heart and soul into helping the approximately 350,000 children and young people affected and their families throughout Switzerland.

To this end, we focus on the following areas:


  • direct financial aid for affected families (since 2014, around 2.2 million has been paid out to affected families)


  • connecting affected families (since 2014, 710 families are in our free KMSK Family Network. To connect them, we hold great family events)


  • Knowledge transfer on the topic of rare diseases for affected families, professionals, media and the public (2022 70 professional articles print/online/TV/radio)


The Association for the Promotion of Children with Rare Diseases relies on donations and legacies from private individuals, support from companies, foundations and business organizations. This is the only way we can continue to sustainably support children and adolescents with rare diseases as well as their parents and siblings in Switzerland. As an independent NPO, we do not receive any funds from the public sector.


www.kmsk.ch


Our objectives and partners

Orientation and support for affected families and professionals in the information jungle! "We saw an urgent need for action and developed the integrative KMSK Knowledge Platform Rare Diseases together with the Winterthur Institute for Health Economics of the ZHAW and the University of Applied Sciences Wallis HES-SO ", says the project manager and managing director of the Support Association for Children with Rare Dise ases Manuela Stier.


The KMSK Knowledge Platform contains all important information on support services and offers for affected families. The more than 710 affected KMSK families played a central role in the development process with their knowledge and experiences. The KMSK knowledge platform was developed together with the 710 affected families from the KMSK family network and therefore precisely reflects their concerns and needs. The project thus follows a participatory approach.


Affected families and professionals were involved in the project at different points in time (from initial interviews and surveys to the testing of platform prototypes). In addition, different experts (e.g. from the field of social counseling of children's hospitals) participated in the two-year development of the web-based KMSK knowledge platform.

Partner

The Zurich University of Applied Sciences (ZHAW) is one of the leading universities of applied sciences in Switzerland and educates around 14,000 students. In its research and development, the university focuses on central societal challenges Challenges such as "social integration" and "digital transformation". For the university as a social knowledge transformer, the cooperation with actors such as the Förderverein KMSK is central and of great importance. In close cooperation with practitioners, the ZHAW conducts application-oriented research studies that are intended to yield the greatest possible direct benefit to society. A team from the Winterthur Institute of Health Economics was involved in the development of this KMSK knowledge platform.

Website

The HES-SO Valais-Wallis is part of the University of Applied Sciences of Western Switzerland (HES-SO). It educates over 2,800 students and makes a significant contribution to economic and social development and innovation, it makes a significant contribution to economic and social development. Due to its geographical location on the German-French language border, it is a particular concern to the scientific discourse and traditions of both language regions and to build Language regions and to act as a bridge between them. The main features of the university are practice-oriented education and training as well as And further education, as well as (research) projects with a high social social benefit. For example, the HES-SO Valais launched the Certificate course in rare diseases, participates in (research) projects on the topic or (research) projects on the topic or cooperates with the association for children with rare diseases together.

Website

Patron

Biogen is one of the oldest independent biotechnology companies active in the field of neuroscience. Today, the company has a leading portfolio of drugs for the treatment of multiple sclerosis and the first approved therapy for spinal muscular atrophy. In addition, Biogen also markets biosimilars and is focused on advancing one of the most diverse pipelines in neuroscience.
Website
founded in Japan in 1781, Takeda is now a leading global biopharmaceutical company with over 50,000 employees in 80+ countries. Takeda Switzerland is headquartered in Zurich. The focus of its 90 employees is on the distribution of medicines for the Swiss market. Takeda's main areas of activity are rare diseases, gastroenterology, neuroscience and oncology.
Website
Interpharma informs the public about issues of importance to the research-based pharmaceutical industry in Switzerland, as well as about the Swiss pharmaceutical market, healthcare and biomedical research. Interpharma works closely with all stakeholders in the healthcare sector, namely in the health care sector, in particular with the representatives of the research pharmaceutical industry in Switzerland and abroad.
Website
Vertex is a global biotechnology company that uses scientific innovation to develop breakthrough medicines for people with serious diseases. Following this mission, we are working on numerous research and development programs in cystic fibrosis (CF, cystic fibrosis) and many other diseases. At Vertex, we are targeting the cause of serious diseases, investing in research and development, bringing together the brightest minds, and daring to innovate in order to provide the best for patients.
Website

Sanofi researches, develops and provides new opportunities for people with rare diseases The more than 350 million patients and their families worldwide often face a long journey of testing, misdiagnosis and consultation with specialists. Sanofi is committed to accelerating this process by providing sustainable, innovative treatments.

Website

Pfizer develops innovative medicines that help prevent, cure or make diseases more tolerable. The goal is for everyone who benefits from Pfizer therapies to receive them. Progress creates hope, and with it the reasonable prospect of a healthier world.

Website

Innosuisse finances science-based innovation projects that industry partners and private or public organizations carry out together with a research partner. In this way, novel products, services or processes can be jointly developed. Innosuisse supports projects in all subject areas.

Website
Raiffeisen Switzerland is an association of all Swiss Raiffeisen banks. Organized on the basis of a cooperative, the 226 independent Raiffeisen banks with a total of 834 branches form the Branches, they form the densest banking network in Switzerland.
AXA is the leading insurance company in Switzerland. Private and Clients benefit from the complete range of insurance solutions Insurance solutions. This ranges from personal, property and Liability insurance, tailor-made life insurance and pension fund solutions, and and pension fund solutions, to banking products with banking partners. The Headquarters of the company is located in Winterthur.